Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specified Use-Results Survey of Zolgensma Intrathecal Injection (Spinal Muscular Atrophy)

NCT07767890 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07767890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07767890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specified Use-Results Survey of Zolgensma Intrathecal Injection (Spinal Muscular Atrophy)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
March 31, 2031
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy